CLSD's Business Model
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Sector & Industry | Healthcare / Biotechnology |
Website | https://www.clearsidebio.com |
CEO (Chief Executive Officer) | George M. Lasezkay Pharm.D., Pharma.D. |
Number of Employees | |
IPO date | June 2, 2016 |
CLSD Latest News
|
|
|
|
|
Contact | |
---|---|
Country | US |
Address | 900 North Point Parkway |
City | Alpharetta |
State | GA |
Phone | 678 270 3631 |
Zip Code | 30005 |
Other Identifiers | |
CIK | 0001539029 |
ISIN | US1850631045 |
CUSIP | 185063104 |
Open | 0.83 |
Previous Close | 0.8123 |
Volume | 114.4 Thou. |
Average Volume | 237.6 Thou. |
Day’s Range | 0.81 – 0.8395 |
52 Week Range | 0.7-1.65 |
MA (50) | 0.8247 |
MA (200) | 0.97161 |
Market Cap | 63.33 Mil. |
Shares Out. | 77.71 Mil. |
Earnings Date | Aug 11, 2025 |
Beta | |
Last Dividend | |
EPS | |
PE | |